Daily Stock List
All Grade Mining, Inc. (HYII)
FeedBlitz, SmallCapInvestorDaily, Michael Stone, PickPennyStocks, Research Driven Alerts, Research Driven Investor, Growing Stocks Reports, Stockdigest Report, OTCtipReporter, and PennyStockScholar reported earlier on All Grade Mining, Inc. (HYII), and we highlight the Company as "One to Watch" here at the QualityStocks Daily Newsletter.
Headquartered in Hackensack, New Jersey, All Grade Mining's mission is to acquire mining concessions in all phases, all sizes and all minerals. All Grade is currently focusing on South America, primarily Chile, and their corporate goal is to bring projects from exploration to exploitation.
At present, the Company owns an iron ore concession in central Chile, III Region - The Salitrosa Property. This property is currently undergoing its environmental impact declaration and feasibility studies allowing All Grade to process greater than 50,000 tons of iron per month. All Grade acquired the Salitrosa iron mine in the Republic of Chile in October of 2011 as their first mining project.
The Salitrosa mine is 28 kilometers from Chanaral and 60 kilometers from the Caldera port. This property is also within 18 kilometers of a national railway to which it could be connected by short line spur. Salitrosa consists of an updated 741 hectares spanning 24 square kilometers. It has an estimated iron ore reserve of more than 40 million metric tons based on magnometric and geological studies done on the property. The Salitrosa property consists of 23 separate mines.
All Grade Mining began site preparation in the third quarter of 2012. They expect to bring production up to 150,000 Metric Tons per month by mid-2013. The Salitrosa project will involve an open pit mine and a dry magnetic concentration plant for the potential production of iron ore concentrates with an average grade of 63.5 percent.
In June 2012, All Grade acquired the Jose Del Transito Project. This copper mine is approximately 3 km north southeast of Ovalle. The mine is currently producing up to 1,100 tons of copper monthly. The Company's intention was to submit permits with the Chilean government to double production by the end of 2012. With a combination of small and large-scale projects, the Company will be able to create cash flow from the small concessions and be able to invest time and money into the exploration of larger scale projects.
In addition, in June, All Grade Mining announced that they entered into an agreement with Foreign Commerce Consultative Services, Inc. (FCCSI) to facilitate the permitting process for the Salitrosa iron property, in addition to executing all of their mining operations. FCCSI is a full-service consulting firm in the mining sector. They provide a complete range of services to manage any project from exploration planning through production and delivery.
We're tracking All Grade Mining, Inc. (HYII) on our radar screens as "One to Watch" this week, here at the QualityStocks Daily Newsletter.
All Grade Mining, Inc. (HYII), closed Thursday's trading session at $0.07, up 40.00%, on 3,559,746 volume with 232 trades. The average volume for the last 60 days is 402,612 and the stock's 52-week low/high is $0.02/$0.90.
Esio Water And Beverage Development Corp. (ESWB)
Today we are reporting on Esio Water And Beverage Development Corp. (ESWB), here at the QualityStocks Daily Newsletter.
Esio Water And Beverage Development Corp. focuses on marketing and servicing multi-serve beverage dispensing systems and beverage products for use in homes and offices in the State of Texas. The beverage system includes countertop and floor stand beverage dispensers that provide hot and cold drinks. Founded in 1988, the Company formerly went by the name Tempco, Inc. They have subsequently changed their corporate name to Esio Water And Beverage Development Corp. The Company is based in Scottsdale, Arizona.
Last week, Tempco announced that FINRA approved a change of the Company's name to "Esio Water and Beverage Development Corp." Effective January 18, 2013, the Company's common shares started trading on the OTC Bulletin Board under the new trading symbol "ESWB". The previous trading symbol was "TEMO". A spokesperson for Esio Water And Beverage Development said that the name change more appropriately reflects the Company's business and strategic goals.
On August 14, 2012 Tempco executed a Regional Developer Agreement (RDA) and three Franchise Agreements (FA) with ESIO Franchising, LLC (ESIO) for the Dallas/Fort Worth region of Texas and three franchises within. Upon the execution of the RDA, Tempco paid $250,000 cash to ESIO. This includes a credit of $70,000 from a payment made earlier in 2012 on a deposit agreement covering 10 other regions with ESIO.
The Company must begin operations of their Regional Development business and first three franchises within one year of the execution of the RDA or forfeit their rights under the RDA and three franchise agreements. In addition, they must sell or open 12 additional franchises in the Territory within the 10-year term of the RDA. The first two must be in operation within the third year after the execution of the RDA.
Under the RDA, once their three franchises are operating, they will receive 50 percent of the initial franchise fees ESIO receives from their franchisees in the Territory and 40 percent of all royalties ESIO receives from their franchisees in the Territory, excluding advertising fund payments. ESIO's patented E-Paks deliver optimally blended national brand and private label juices, sport drinks, vitamin waters, teas and coffees.
Esio Water And Beverage Development Corp. (ESWB), closed Thursday at $0.28, up 40.00%, on 3,000 volume with 1 trade. The average volume for the last 60 days is 1,327 and the stock's 52-week low/high is $0.15/$0.50.
MEDL Mobile Holdings, Inc. (MEDL)
FeedBlitz reported last week on MEDL Mobile Holdings, Inc. (MEDL), Mina Mar Marketing Group did earlier, and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTC Bulletin Board, MEDL Mobile Holdings, Inc. develops, acquires and publishes a growing library of mobile applications. These applications perform specific functions for the user on the Apple and Android platforms. The Company licenses their technology and performs custom development for key clients such as Monster.com, the New York Times Company, Teleflora, Telefonica and Medtronic. MEDL Mobile has their headquarters in Fountain Valley, California.
The Company is establishing a business model in which they expect to generate multiple revenue streams. These streams include development fees, download and in-app purchases, advertising, sponsorship and licensing of technology. MEDL Mobile enters into partnerships to mobilize and monetize Intellectual Property (IP) with prominent names such as Encyclopedia Britannica, MTV's Pauly D, Cheech & Chong, Rampage Jackson and Marlee Matlin.
The Company's growing Mobile Brain collects user analytics. It processes user data to create better distribution and monetization of mobile applications. MEDL Mobile's Software Development Kit (SDK) consists of a growing collection of tools that have undergone design to help developers to better market and monetize their mobile applications.
Last week, MEDL Mobile announced that the Company has partnered with EUE/Sokolow and Producer Damon Harman with the goal of turning MEDL Mobile's popular App Incubator platform into a television show. The App Incubator first launched in 2009. It allows anyone with an idea for an app to submit his or her concept. Since launching, MEDL Mobile has received over 125,000 app submissions. The Company has developed dozens of apps from the Incubator - with some reaching as high as #1 on the Apple App Store.
Mr. Dave Swartz, MEDL Mobile President and Chief Creative Officer, said, "Demand for our App Incubator continues to be strong with new ideas coming in every day. But what's more fascinating than the ideas themselves are the people behind them. Television is the perfect medium to bring the Incubator to life in a big way."
MEDL Mobile Holdings, Inc. (MEDL), closed Thursday's session at $0.175, up 16.67%, on 387,850 volume with 73 trades. The average volume for the last 60 days is 29,518 and the stock's 52-week low/high is $0.071/$1.15.
Provectus Pharmaceuticals, Inc. (PVCT)
Yesterday, plrinvest reported on Provectus Pharmaceuticals, Inc. (PVCT), Streetwise Reports, PennyTrader Publisher did earlier, and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Provectus Pharmaceuticals, Inc. is a development-stage oncology and dermatology biopharmaceutical company that lists on the OTC Market's OTCQB. The Company specializes in developing oncology and dermatology therapies. Their oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the Food and Drug Administration (FDA) for their melanoma and hepatocellular carcinoma indications. Provectus Pharmaceuticals has their headquarters in Knoxville, Tennessee.
The design of the Company's novel oncology drug PV-10 is to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing the potential for systemic side effects. Their dermatological drug PH-10 also targets abnormal or diseased cells. The current focus is on psoriasis and atopic dermatitis. Provectus recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Moreover, Provectus Pharmaceuticals has developed innovative biotechnologies to augment vaccine production and detect viruses. This includes a cutting-edge "virus hunter" method. The Company is also preparing to spinout the subsidiary that contains their novel Over-The-Counter (OTC) skin care products. Additionally, Provectus is looking to license patented technologies for therapeutic and cosmetic medical devices.
Yesterday, the Company announced that data on PV-10 would be presented in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination of PV-10 immuno-chemoablation and systemic anti-CTLA-4 antibody therapy in murine models of melanoma," authored by Eric Wachter, Savannah Blair, Jamie Singer and Craig Dees, will be presented on April 10, 2013.
Today, Provectus Pharmaceuticals announced that they launched a free mobile shareholder investor relations application. The "Provectus IR" App is available for download from the App Store and from the Google Play Store. The investor relations application offers immediate portable access to the Company's latest news, financial information, presentations, and factsheet.
Provectus Pharmaceuticals, Inc. (PVCT), closed Thursday's trading session at $0.60, down 0.83%, on 104,300 volume with 26 trades. The average volume for the last 60 days is 15,305 and the stock's 52-week low/high is $0.431/$0.99.
Bingo.com, Ltd. (BNGOF)
Breaking Stock Reports reported previously on Bingo.com, Ltd. (BNGOF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Bingo.com, Ltd. is the parent company of the Bingo.com group of companies, which own the popular online gaming community www.bingo.com. This site provides a variety of Internet games. These include bingos, slots, video pokers, and casino games for free and money. In addition, the Company provides other forms of entertainment, including an online community and chat rooms. Bingo.com's shares trade on the OTCQB. Founded in 1987, the Company has their corporate headquarters in Anguilla, British West Indies.
The Bingo.com website has attracted millions of visitors from more than 200 nations. The website is one of the most recognized and most visited bingo entertainment destinations on the Internet. Bingo.com operates their multi-language and multi-currency bingo and casino system as part of the Unibet partner program. The Company's web portal offers multiplayer bingo, slot machines, sweepstakes, and more.
There are two main branches to the Company's business. It depends upon where in the world the domain is accessed. If accessed from North America, the website and the various free-to-play games are operated by Bingo.com's wholly owned Anguilla subsidiary, Coral Reef Marketing, Inc. If accessed from other parts of the world, the website is operated under contract by Maria Services Ltd., a subsidiary of Unibet Group plc. Bingo.com has more than 1,995,000 registered players and more than 800 new users daily.
In November 2012, Bingo.com announced their unaudited financial results for the third quarter ended September 30, 2012. Net Income for the period amounted to $29,002. This is in comparison to a net loss of ($28,908) in the third quarter of 2012.
Total Revenue for the quarter was $457,748. This represents an increase of 32 percent from revenue of $347,742 in the second quarter of 2012. The Company had cash of $574,787 and positive working capital of $980,660 at September 30, 2012. This compares to cash of $787,524 and positive working capital of $1,058,631 at December 31, 2011.
In December, Bingo.com announced that they closed an additional private placement of one million common shares at $0.45 per share to raise net proceeds of $450,000. The shares have been placed with a non-U.S. private company. Bingo.com will use the funds raised in this private placement to expand their marketing activity further and to finance internal projects.
Bingo.com, Ltd. (BNGOF), closed Thursday at $0.40, even for the day. The average volume for the last 60 days is 10,758 and the stock's 52-week low/high is $0.25/$0.75.
Borneo Resource Investments Ltd. (BRNE)
StockGuru reported previously on Borneo Resource Investments Ltd. (BRNE), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Borneo Resource Investments Ltd.'s mission is to develop a platform of prime quality energy assets and export potential to explore and develop coal reserves primarily in the East Kalimantan and West Papua regions of the Republic of Indonesia. The Company has their wholly owned subsidiary Interich International Ltd. Borneo's strategy is to continue to acquire prime concessions and develop a "land bank" of assets to buy and sell assets and mine coal with strategic partners. Borneo Resource Investments lists on the OTC Market's OTCQB; the Company has their headquarters in Bothell, Washington, as well as an office in Admiralty, Hong Kong.
Borneo operates as an aggregator of natural resource concession assets in Indonesia. Each concession is a contractual right to explore or develop natural resources in a specific land area. Their intention is to explore and develop thermal coal concessions and licenses. In addition, they are looking to acquire additional natural resource assets, including thermal coal, timber, and precious metals.
Currently, Borneo Resource Investments holds one coal mining concession acquired by Interich from PT Chaya Meratus Primecoal. With the exception of this one concession, Borneo has only entered into Memorandums Of Understanding or Letters Of Intent with concession holders that are not legally binding on either the concession holder or the Company until the parties enter into definitive agreements that will require them to pay fees and conduct due diligence. Upon entering into agreements to acquire concessions, the Company will market the properties to mining companies and other interested parties.
Yesterday, Mr. Nils Ollquist, Chairman and CEO of Borneo Resource Investments issued a report to the Company's shareholders. Included in the report was the following statement, "Borneo Resource Investments Ltd. continues to hold its thermal coal concession holdings and rights. The Company's short term and long term options with regard to the monetization of these assets and rights are continually being reviewed by management. Borneo will also continue to consider the acquisition of additional thermal coal concessions. Recently, Borneo has also begun to expand its concession acquisition activities in Indonesia to include precious metals. We are currently evaluating a number of gold concessions, specifically around the City of Manado in the North Sulawesi Province of Indonesia, one of the richest gold mining areas in the country. We anticipate that we will be able to announce specifics with regard to these concession assets over the course of the next 3 months."
Borneo Resource Investments Ltd. (BRNE), closed Thursday's trading at $0.85, down 5.56%, on 500 volume with 1 trade. The average volume for the last 60 days is 1,502 and the stock's 52-week low/high is $0.42/$2.90.
ReliaBrand, Inc. (RLIA)
We are highlighting ReliaBrand, Inc. (RLIA), here at the QualityStocks Daily Newsletter.
ReliaBrand, Inc. owns and manufactures the Adiri® brand of infant feeding products. Adiri® is the most highly awarded baby bottle in the history of the category. It has international recognition for its superior medical benefits and innovative design. ReliaBrand's near term strategy is to launch Adiri® sales online and by distribution to retail chains in Canada, the U.S. and China. Their long-term strategy is driven by product development and the aggressive acquisition of innovative single product brands. ReliaBrand is based in Kelowna, British Columbia. The Company's shares trade on the OTC Bulletin Board.
ReliaBrand's long-term strategy is to develop licensing and joint venture relationships around the world. The Company is a manufacturer and designer focusing on the delivery of BPA-free plastic products for infants to toddlers. Their products include the Adiri® NxGen™ Nurser, the Adiri® Transitional Nurser, Adiri-Phant® Sippy Cups, Adiri® Training Cups, Adiri® Teething Rings and Pacifiers, and Adiri® Accessories.
ReliaBrand™ employs the innovation of material sciences to produce products from food grade silicone and plastics that are 100 percent polycarbonate, and BPA-free. The Company's products are heat resistant as well as dishwasher safe. In addition, these products undergo a sterile manufacturing and packaging process. ReliaBrand holds many worldwide patents on products.
The Company's flagship product Adiri® Ultimate Nurser has won 16 international awards. These include the gold medal at the prestigious Medical Design Excellence Awards, The D&AD Award, and the prestigious 2010 JMPA International Award at the world's largest expo for Juvenile Products, The ABC Kid's Expo. Adiri® received recognition for its design achievements by being inducted into the Pasadena Museum of California Art.
Today, ReliaBrand announced that Walmart Canada would be the exclusive national retailer of the new Adiri® NxGen® product line in Canada. The new Adiri® NxGen® products will first be available in 150 selected Walmart stores across Canada. The NxGen® bottles are the latest version in the line of patented Adiri® Nurser's. They feature new 5.5 ounce Newborn and the 9.5-ounce infant sizes in new colors. Additionally, the new Adiri® NxGen® offering includes replaceable nipples in varying flow rates to accommodate all the infant feeding transitional stages.
ReliaBrand, Inc. (RLIA), closed Thursday's trading session at $0.21 up 23.63%, on 67,200 volume with 21 trades. The average volume for the last 60 days is 5,903 and the stock's 52-week low/high is $0.04/$1.01.
Bell Copper Corp. (BCU.V)
Today we are highlighting Bell Copper Corp. (BCU.V), here at the QualityStocks Daily Newsletter.
Bell Copper Corp. is a TSX Venture Exchange listed company focusing on copper exploration in North America. Dr. Timothy Marsh leads the Company's development and exploration initiatives. The Company formerly went by the name Bell Resources Corp. They changed their name to Bell Copper Corp. in April 2008. The Company has their corporate headquarters in Vancouver, British Columbia.
Bell Copper's interests included the Van Dyke assets. However, on July 9, 2012, Bell Copper signed a purchase agreement with Copper Fox Metals, Inc. Bell Copper agreed to sell the Van Dyke and Sombrero Butte assets. Copper Fox will acquire 100 percent of the Properties by paying to Bell Copper CDN$2,000,000 in cash and assuming Bell Copper's continuing obligations in respect of the Properties.
Bell Copper also has their Kabba asset. The Company is targeting a truncated, major Mo-Cu porphyry system that lies under shallow cover on their land holdings at the Kabba Project.
On April 11, 2012, Bell Copper announced that they entered into a binding Letter Of Intent (LOI) with AKA Ventures, Inc. This allows AKA to earn a 60 percent interest in Bell Copper's wholly owned Kabba molybdenum-copper project in Mohave County, Arizona. AKA can earn a 60 percent interest in the Property; this is through expending CDN$6 million on exploration and other work on the Property and by issuing to Bell Copper 10,000,000 common shares of AKA over a three-year period.
In addition, Bell Copper has their La Balsa asset in Michoacan, Mexico. The next major milestone here is Feasibility. The La Balsa Project has an NI 43-101 Resource. The Company believes it presents considerable geological evidence for the discovery of further Cu mineralization on the property.
In December, Bell Copper announced that they implemented a reconstitution of their Board of Directors with the appointments of Dr. Timothy Marsh (the former President of Bell), Brian Leeners and Francis Ling as Directors of the Company. These have replaced the previous Board consisting of Michael Werner, Keith Droste and Richard Ternieden. As part of the Board reconstitution, Mr. Werner resigned as Bell's Chief Executive Officer and Dr. Marsh was appointed to this office.
Furthermore, in December, Bell Copper announced that they entered into a binding LOI with Phoenix Copper Corp. Phoenix has been granted an option to acquire a 51 percent interest in and to the Kabba Project. Phoenix may earn a 51 percent interest in the Property by completing $5 million in expenditures on the Property on or before the date, which is five years from the date of the LOI.
Bell Copper Corp. (BCU.V), closed Thursday's trading session at $0.01, even for the day, on 500 volume. The stock's 52-week low/high is $0.01/$0.11.
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.129, up 7.50%, on 243,130 volume with 21 trades. The stock’s average daily volume over the past 60 days is 59,069, and its 52-week low/high is $0.0069/$0.13
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Receives Microsoft “Be What’s Next” Award
Viscount Systems Awarded New U.S. Government Contract
Viscount Systems To Secure Canadian Hotel Chain
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.245, up 6.52%, on 177,140 volume with 37 trades. The stock’s average daily volume over the past 60 days is 145,346, and its 52-week low/high is $0.161/$0.65.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Positive Animal Efficacy Results in Liver Disease Program
International Stem Cell Corporation to Participate in Biotech Showcase 2013 on January 7th
Lifeline Skin Care a Subsidiary of ISCO Announces New Sales and Multi-Media Marketing Campaigns
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.068, up 2.26%, on 3,401,268 volume with 132 trades. The stock’s average daily volume over the past 60 days is 3,249,230, and its 52-week low/high is $0.0275/$0.178.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis to Present at the 6th Annual OneMedForum
Advaxis Appoints Daniel J. O'Connor to Senior Vice President, Chief Legal and Business Development Officer
Advaxis Receives Preliminary Approval for Sale of Losses from State of NJ Economic Development Authority
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.77, even for the day, on 1,900 volume with 3 trades. The stock’s average daily volume over the past 60 days is 1,696, and its 52-week low/high is $0.06/$3.10.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
VistaGen's lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
VistaGen Therapeutics Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium
A recent article published by Seeking Alpha, titled “Supreme Court Decision Is Bullish For Stem Cell Companies,” reviews the recent high court decision that allows medical universities and science foundations to receive federal funding for embryonic stem cell research. Now supported by the federal government, the stem cell industry is anticipated to be a $6.6 billion market by 2016, more than 50% greater than its present size.
To read the complete article, visit: http://seekingalpha.com/article/1120881
Peter Harengel, author of the article, provided an overview of the progress taking place in the industry as companies continue to move forward with their stem cell research. VistaGen Therapeutics, for instance, recently announced a significant advance in its development of LiverSafe 3D™, a human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism before animal or human testing. As with its CardioSafe 3D™ product, this bioassay system was designed to be used with modern medicinal chemistry to generate safer, proprietary chemical variants (“drug rescue variants”) of once-promising drug candidates, as well as identify product failures earlier in the cost curve.
Companies active in stem cell research are now much more attractive for a variety of factors. The election in Washington, D.C. has brought clarity to the health care sector, overall. The major players know what to expect and can now move forward. The recent Supreme Court decision will now focus the attention of many on stem cell research as more federal funding will enter the sector. Also of significance is that the political uncertainty is gone regarding stem cell research.
2013 is poised to introduce a new flood of excitement in this up-and-coming health care market.
Cardium Therapeutics is a health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative health products. As an important part of its overall strategy, the company has entered the health and wellness market through the acquisition of To Go Brands, a developer of easy-to-use nutraceuticals. To Go Brand products include energy boosters, probiotics, antioxidants, metabolism regulators, and various vitamin and mineral supplements, all in easy-to-use forms that make proper nutrition simple.
An example is Neo-ChillTM, a special dietary supplement that promotes relaxation without drowsiness. Neo-Chill helps both the body and mind to relax, but without dulling the senses or creating the sluggish feeling often found with other products. Neo-Chill contains Suntheanine®, a patented, proprietary L-theanine (an amino acid) also found in green tea. Clinical studies show that Suntheanine, in doses of between 50 mg and 200 mg, naturally stimulates alpha waves – specific brain activity which is associated with a relaxed but alert mental state. Given the known negative health effects of stress, Neo-Chill is designed for anyone dealing with the all too common pressures of work or home. It reduces stress and promotes overall relaxation and mental calmness.
In addition to marketing its many health products, To Go Brands provides general health information through social networking and at its own site. An example is their blog, where health-conscious viewers can see articles such as the following:
• The Benefits Of Probiotics, Why Bacteria Can Be Good For You
• Surprising Benefits Of Folic Acid
• How To Better Achieve And Maintain Weight Loss
• The Benefits Of Whey Protein Isolate Versus Concentrate
• Omega 3 Fatty Acids Without Fish Oil
For additional information, visit www.CardiumTHX.com and www.ToGoBrands.com
The global transition from power production based on fossil fuels, sources that pour billions of tons of carbon dioxide and other greenhouse gases into the atmosphere every year, to solar and other renewables is usually viewed in terms of large power plants. But the development, distribution, and use of what are called micro-solar installations could be the one of the most important contributions in the global struggle to reduce greenhouse gases and global warming.
Micro-solar installations are small-scale solar power generators that can be used off-the-grid for all sorts of purposes. The reason they are so important is that they can effectively replace millions of highly polluting energy sources used in remote locations that don’t have easy access to electricity in developing countries around the world. For example, instead of using kerosene to produce lighting, pumping out carbon dioxide as well as particular pollution, micro-solar generators can be used to generate the same power with no pollution footprint. India claims to already have installed over a million such systems, with millions more to go. China, the source of more greenhouse gases than even the U.S., is also a huge potential market for such systems, as is virtually the entire continent of Africa.
Bergamo Acquisition has developed a unique and effective funding process allowing the company to pursue its strategy of building a diverse acquisition portfolio of growth companies. One of these acquisitions is dedicated to the development and distribution of solar generators for cell phone towers, solar generators for home and industry applications, and solar operated tube well water pumping systems for developing countries in Asia, with potential worldwide application. Their water pumping system, for instance, uses a PV solar array to power the pumping of vital water in remote locations, avoiding the use of small-scale engines which are some of the worst polluters.
For additional information, visit www.BergamoCorp.com
Yesterday, global intravascular robotics leader Hansen Medical announced that its Magellan Robotic System was utilized in two successful live endovascular aortic aneurysm repair (EVAR) cases. Both cases were performed by Baptist Cardiac & Vascular Institute (Baptist Hospital of Miami) Founder and Medical Director Dr. Barry Katzen, who is also a course director at ISET.
ISET is a prominent meeting for interventional radiologists, cardiologists, and endovascular surgeons. The live cases, such as those performed by Dr. Katzen as part of the TCT conference in October 2012, help demonstrate the real-world medical utility of Hansen Medical’s robotic system and its ability to enhance endovascular procedures. Today’s cases demonstrated that robotic catheters can play a valuable role in vascular procedures, and they also indicate the technology’s potential in future clinical applications.
The Magellan Robotic System is based on the flexible robotic technology used in Hansen Medical’s Sensei-X Robotic Catheter System, which is currently being sold in the United States and Europe and has been used in almost 10,000 patients. The Magellan system, however, includes various key enhancements. The Magellan system provides solid catheter stability for placement of therapeutic devices and has been designed to enable predictable procedure times and increased case throughput. The system also allows for independent, individual robotic control of the distal tips of both the outer sheath and the inner leader catheter, as well as robotic manipulation of standard guidewires. The Magellan system has been designed to allow for sufficient extension inside the body to access hard-to-reach peripheral anatomy, and it also preserves the open architecture featured in the Sensai System, allowing for the subsequent use of many 6F therapeutic devices currently on the market. The Magellan system is also designed to potentially reduce exposure to radiation as well as fatigue for physicians through use of a remote physician workstation.
Based in Mountain View, Calif., Hansen Medical is the world leader in intravascular robotics, developing products and technology designed to enable the accurate positioning, manipulation, and control of catheters and catheter-based technologies. The company’s Magellan Robotic System, Magellan Robotic Catheter, and related accessories – intended to facilitate navigation to anatomical targets in the peripheral vasculature and subsequently provide a conduit for manual placement of therapeutic devices – have undergone both CE marking and 510(k) clearance and are commercially available in the European Union and the U.S.
In the European Union, the company’s Sensei-X Robotic Catheter System and Artisan Control Catheter are cleared for use during electrophysiology (EP) procedures, such as guiding catheters in the treatment of atrial fibrillation (AF), and the Lynx Robotic Ablation Catheter is cleared for the treatment of AF. This robotic catheter system is compatible with fluoroscopy, ultrasound, 3-D surface map and patient electrocardiogram data. In the United States, the company’s Sensei X Robotic Catheter System and Artisan Control Catheter were cleared by the U.S. Food and Drug Administration for manipulation and control of certain mapping catheters in EP procedures.
For more information, visit www.hansenmedical.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) to Present at the 6th Annual OneMedForum
- Bergamo Acquisition Corp. (BGMO) Signs Investment Agreement
- Consorteum Holdings, Inc. (CSRH) Files Form 10-K Report With the Securities and Exchange Commission
- Cardium Therapeutics, Inc. (CXM) To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
- The Guitammer Company Inc. (GTMM) Insiders Acquire An Aggregate Of 156,000 GTMM Shares In Open Market Purchases
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- International Stem Cell Corp. (ISCO) Announces Positive Animal Efficacy Results in Liver Disease Program
- Loans4Less.com, Inc. (LFLS) Provides Preliminary Financial Results for Year Ended December, 31 2012
- TNI BioTech Inc. (TNIB) Acquires the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists for the Treatment of Inflammatory and Ulcerative Diseases of the Bowel
- Viaspace, Inc. (VSPC) Giant King Grass Energy Crop Growing in Hawaii
- Viscount Systems, Inc. (VSYS) Systems Awarded New U.S. Government Contract
- VistaGen Therapeutics, Inc. (VSTA) Becomes Member of Centre for Commercialization of Regenerative Medicine Consortium